Posts

Replimune’s Twice‑Rejected Melanoma Drug Prevails in FDA Adcomm Vote

on

Capricor Shares Plunge After FDA Says DMD Therapy Lacks Efficacy Ahead of Advisory Committee Meeting

on

FDA Adcomm Backs Popular Wellness Peptides Despite Staff Concerns

on

Emideltide narrowly voted down by FDA peptide advisory panel on Day 2

on

Makary’s FDA Reforms Continue to Advance Amid Leadership Turmoil

on

Moderna Once-Rebuffed mRNA Flu Shot to Face Scrutiny From FDA AdComm

on

Paul Offit, RFK Jr. Critic, Removed from Key FDA Vaccine Panel

on

Conflicts of Interest Among Federal Vaccine Advisors at Historic Lows Through 2024

on

HHS Revives '90s-Era Task Force to Improve Childhood Vaccine Safety

on

RFK Jr. Reportedly Weighs Preventive Services Panel Revamp, Raising Risks for HIV PrEP Drugmakers

on

FDA Advisory Committee Rejects Lundbeck and Otsuka's PTSD Bid for Rexulti

on

FDA Advisory Committee Votes Against GSK's Blenrep in Multiple Myeloma

on

FDA Flags Eye Safety Concerns as GSK Seeks Blenrep's US Return

on

RFK Jr.'s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

on

Sen. Bill Cassidy Calls for Deferral of CDC Vaccine Meeting After RFK Jr. Panel Shakeup

on

FDA Expects 'Timely Availability' of Covid Shots as Advisors Update Formula Recommendation

on

FDA Advisory Committee Unanimously Votes Against Expanding Pfizer's Prostate Cancer Drug Combo

on

FDA Advisory Committee Splits Votes on Genentech and J&J Cancer Drugs

on

FDA Delays Decision on Biohaven's Troriluzole for Rare Disease, Plans Advisory Committee Review

on

FDA Vaccine Advisory Committee to Determine 2025-2026 COVID-19 Vaccine Formulation

on